 Intercept Pharmaceuticals Inc NASDAQ: ICPT has announced results from a new analysis examining obeticholic acids OCA potential to improve transplant-free survival in patients with primary biliary cholangitis PBC. In the analysis, 209 patients treated with OCA in the POISE long-term safety extension study had significantly greater transplant-free survival than patients in the external control groups. 